Potential risk for developing severe COVID-19 disease among anabolic steroid users.
| Autor: | Cadegiani F; Adrenal and Hypertension Unit, Division of Endocrinology and Metabolism, Department of Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo (EPM/UNIFESP), São Paulo, São Paulo, Brazil.; Corpometria Institute, Brasilia, Distrito Federal, Brazil., Lin EM; Department of Dermatology, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA., Goren A; Applied Biology Inc, Irvine, California, USA., Wambier CG; Department of Dermatology, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA carlos_wambier@brown.edu. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | BMJ case reports [BMJ Case Rep] 2021 Feb 26; Vol. 14 (2). Date of Electronic Publication: 2021 Feb 26. |
| DOI: | 10.1136/bcr-2021-241572 |
| Abstrakt: | A severe case of COVID-19 was observed in an otherwise healthy 28-year-old man who had taken oxandrolone 40 mg/day as an anabolic steroid. The patient had been taking oxandrolone for enhanced bodybuilding 30 days prior to presenting to an outpatient clinic with COVID-19 symptoms. The patient reported that his symptoms have rapidly worsened over the course of 4 days prior to presenting at the clinic. As part of an experimental antiandrogen treatment for hyperandrogenic men suffering from COVID-19, he was administered a single 600 mg dose of the novel antiandrogen proxalutamide. Twenty-four hours after administration of this dose, marked improvement of symptoms and markers of disease severity were observed. To our knowledge, this is the first case that potentially links anabolic steroid use to COVID-19 disease severity. Competing Interests: Competing interests: None declared. (© BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|